Pure Global AI
NCT06157528Not yet recruiting

Diagnosis of Pelvic Endometriosis in MRI

Diagnosis of Pelvic Endometriosis: a Preliminary Study on the Added Value of R2*MFGRE Sequence in MRI
Zhenshen MaClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Endometriosis
Drug/Device/Intervention
Magnetic resonance imaging
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Zhenshen Ma
Funder
Qianfoshan Hospital
Timeline & enrollment
Phase
N/A
Start date
Dec 20, 2023
End date
Dec 01, 2029
Enrollment
100 participants
Primary outcome

Measuring the number of lesions

Summary

Purpose： Evaluate the feasibility of R2 star multiple fast gradient recalled echo (R2*MFGRE)
 imaging in the diagnosis of pelvic endometriosis.
 
 One hundred patients with suspected endometriosis underwent routine pelvic MRI and R2*MFGRE
 imaging. Clinical diagnosis was pathologically confirmed one month after MRI examination.
 Three radiologists who were blinded to the pathological results evaluated the numbers of
 ovarian endometriomas (OMAs) and deep in-filtrating endometriosis (DIE) lesions using routine
 MRI and its combination with R2*MFGRE. MRI changes of lesion size before and after estrogen
 therapy.

ICD-10 classifications
EndometriosisOther endometriosisEndometriosis, unspecifiedEndometriosis of uterusEndometriosis of ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06157528
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06157528 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhenshen Ma and is currently Not yet recruiting. The study focuses on Endometriosis. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.